<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269684</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ACH04</org_study_id>
    <nct_id>NCT01269684</nct_id>
  </id_info>
  <brief_title>Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients</brief_title>
  <acronym>HERMES</acronym>
  <official_title>A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety and tolerability of an immediate
      conversion from Tacrolimus to everolimus in stable renal allograft recipients.

      Interest in developing CNI-free regimens using other agents such as the proliferation signal
      inhibitor everolimus.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient has never been included in the trial
  </why_stopped>
  <start_date type="Actual">August 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Month 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Week 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Month 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Month 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine safety laboratory</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>Weeks 1, 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>Months 1, 2, 4 and 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Primary or secondary renal transplantation in the past 12-36 months.

          -  Current immunosuppressive therapy consisting of Tacrolimus together with MMF
             +/-corticosteroids.

          -  Moderately impaired renal function

        Exclusion criteria

          -  Multi-organ recipients or previous transplantation with an organ other than a kidney.

          -  Acute rejection episodes in the last 6 months.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>renal</keyword>
  <keyword>transplantation</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>everolimus</keyword>
  <keyword>stable allograft recipients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

